9
Participants
Start Date
December 31, 2006
Primary Completion Date
August 31, 2008
Study Completion Date
September 30, 2008
GM-CSF
fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
thalidomide
Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
docetaxel
Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
The Methodist Hospital Research Institute, Houston
Collaborators (1)
Bayer
INDUSTRY
The Methodist Hospital Research Institute
OTHER